Tezampanel (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name) (developmental code names LY-293,558, LY-326,325, NGX-424) is a drug originally developed by Eli Lilly[1] which acts as a competitive antagonist of the AMPA and kainate subtypes of the ionotropic glutamate receptor family,[2][3] with selectivity for the GluR5 subtype of the kainate receptor.

[4][5] It has neuroprotective[6] and anticonvulsant properties,[7] the former of which may, at least in part, occur via blockade of calcium uptake into neurons.

[8] Tezampanel has a range of effects which may be useful for medicinal purposes, as well as its applications in scientific research.

It suppresses both the withdrawal symptoms from morphine and other opioids,[9][10][11] and the development of tolerance,[12] as well as having antihyperalgesic[13] and analgesic effects in its own right.

[14][15][16][17][18] It also has anxiolytic effects in animal studies and has been suggested as a candidate for the treatment of anxiety in humans.